Role of PET/CT in Peritoneal Deposits Assessment
1 other identifier
observational
50
0 countries
N/A
Brief Summary
• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2024
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 14, 2023
CompletedFirst Posted
Study publicly available on registry
November 18, 2023
CompletedStudy Start
First participant enrolled
January 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 15, 2026
CompletedNovember 18, 2023
November 1, 2023
2 years
November 14, 2023
November 14, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
role of pet/ct in peritoneal deposits assessment
Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits
2 years
Interventions
• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
Eligibility Criteria
Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits
You may qualify if:
- Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
You may not qualify if:
- Patients unable to sit calm without movement during imaging.
- Severely ill patients.
- Patients unable to sleep in a fixed position for 20 minutes.
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Dawson H, Kirsch R, Messenger D, Driman D. A Review of Current Challenges in Colorectal Cancer Reporting. Arch Pathol Lab Med. 2019 Jul;143(7):869-882. doi: 10.5858/arpa.2017-0475-RA. Epub 2019 Jan 23.
PMID: 30672337BACKGROUNDHusain A, Chi DS, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP. The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol. 2001 Jan;80(1):44-7. doi: 10.1006/gyno.2000.6036.
PMID: 11136568BACKGROUNDPatel CM, Sahdev A, Reznek RH. CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging. 2011 Aug 24;11(1):123-39. doi: 10.1102/1470-7330.2011.0016.
PMID: 21865109RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- assistant lecturer
Study Record Dates
First Submitted
November 14, 2023
First Posted
November 18, 2023
Study Start
January 1, 2024
Primary Completion
January 1, 2026
Study Completion
March 15, 2026
Last Updated
November 18, 2023
Record last verified: 2023-11